Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Distribution expansion

10 Mar 2009 07:00

RNS Number : 5744O
LiDCO Group Plc
10 March 2009
 



Press Release 

10th March 2009

LiDCO Group Plc

("LiDCO" or the "Company")

Distribution Expansion in Germany

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce further expansion of its distribution network. The Company has signed a distribution agreement for the sale of its LiDCOrapid Monitor and disposables in Germany with Absolute Medical GmbH & Co. KG based in RatingenGermany. With LiDCO's existing north German distribution partner, the agreement gives LiDCO access to the biggest hemodynamic monitoring market in Europe.

With a population of 82 million people, Germany ranks as the third largest medical device market in the world (behind the USA and Japan) and represents 36% by value of the European medical device marketAt around 10.6% of GDP, healthcare expenditure in Germany is currently at a high level creating a demand for sophisticated medical equipment which has demonstrated significant improvements in clinical outcome.

Absolute Medical was recently founded by Bradley Gould an experienced CEO with 28 years of experience in the global medical device industry. Absolute Medical's focus is on sales and distribution of advanced medical devices in Germany to hospital acute care, critical care and anaesthesia departments. 

Absolute Medical's CEO Mr Bradley Gould commented "We are very excited to have the opportunity to introduce this new technology to the largest European hemodynamic monitoring market. We have great belief in LiDCO's products and are confident that with our deep knowledge of the hemodynamic monitoring market in Germany, we expect to have great success marketing the LiDCOrapid.

Dr Terry O'Brien, CEO LiDCO Group plc, commented:  "We are delighted to have further broadened our distribution, which means we now have sales reach to the majority of EuropeThe LiDCOrapid is an innovative solution that provides a cost effective, highly accurate solution for monitoring high-risk surgical patients. Working with two distribution partners in Germany means that LiDCO now has full access to the biggest medical device market in Europe."

- ENDS - 

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com 

Panmure Gordon and Co

Edward Farmer/ Katherine Roe

+44 (0)20 7459 3600

www.panmure.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0)20 7398 7728

simone.alves@abchurch-group.com 

www.abchurch-group.com 

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single patient use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors

LiDCO Distribution Network:

The Company sells direct in the UK, direct and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGGFNLNGLZM
Date   Source Headline
29th Mar 20167:00 amRNSRegulatory approval in China
24th Mar 20167:00 amRNSMaster distribution agreement & other distributors
15th Mar 20167:00 amRNSLaunching the new LiDCOunity at ISICEM Brussels
4th Mar 20164:31 pmRNSHolding(s) in Company
2nd Mar 20165:06 pmRNSBlock Listing Review
8th Feb 20167:00 amRNSTrading update
2nd Feb 20163:52 pmRNSHolding(s) in Company
23rd Nov 20157:00 amRNSMaster distribution agreement
16th Nov 20154:35 pmRNSDirector's Dealing
13th Oct 20158:30 amRNSUS purchasing agreement with US hospitals group
13th Oct 20157:00 amRNSHalf Yearly Report
23rd Sep 201510:03 amRNSNotice of Results
2nd Sep 20157:00 amRNSTrading update and notice of results
17th Aug 20157:00 amRNSFormal appointment of Chief Executive Officer
31st Jul 20157:00 amRNSBlock Listing Review
15th Jun 20152:27 pmRNSBoard appointment and grant of share options
11th Jun 20157:00 amRNSJapan reimbursement for LiDCOrapidv2 disposables
13th May 201511:45 amRNSResult of AGM
6th May 20157:01 amRNSCEO and Board Appointment
5th May 20151:32 pmRNSPosting of Annual Report & Notice of AGM
23rd Apr 20157:00 amRNSLiDCO data presented at London Forum
14th Apr 20157:00 amRNSHolding in Company
1st Apr 201512:49 pmRNSDirector/PDMR Shareholding
31st Mar 20157:01 amRNSLIDCOrapid v2 cleared for sale in Japan
31st Mar 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSShowcasing Portable LiDCO Stand System at ISICEM
10th Mar 20157:03 amRNSNotice of Results
2nd Mar 20156:14 pmRNSHolding(s) in Company
17th Feb 20157:00 amRNSFurther clinical support for LiDCOrapid
12th Feb 20157:00 amRNSTrading update and notice of results
30th Jan 201512:20 pmRNSBlock listing review
17th Dec 20142:39 pmRNSHolding(s) in Company
1st Dec 20142:39 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNSFurther clinical support for LiDCOrapid
12th Nov 20145:15 pmRNSHolding(s) in Company
7th Nov 201412:03 pmRNSHolding(s) in Company
3rd Nov 20145:49 pmRNSHolding(s) in Company
16th Sep 20147:01 amRNSBoard Announcement
16th Sep 20147:00 amRNSHalf Yearly Report
21st Aug 201411:39 amRNSNotice of Results
18th Aug 20147:00 amRNSTrading update
31st Jul 20141:46 pmRNSBlock Listing Review
30th Jul 20147:00 amRNSFurther clinical support for LiDCO products
11th Jun 201412:45 pmRNSResult of AGM
11th Jun 201411:49 amRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
23rd May 20141:51 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20144:01 pmRNSHolding(s) in Company
21st May 20147:00 amRNSMonitors Link with NantHealth's DeviceConX System
20th May 20147:00 amRNSResults of the OPTIMISE study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.